Sambad comes to us most recently from Nirogy Therapeutics where he led the biology team to execute IND enabling studies of Nirogy’s lead small molecule inhibitor. He also led studies that identified mechanism of action of Nirogy’s metabolic inhibitor in direct cancer cell killing and activation of antitumor immunity. Before joining Nirogy, Sambad did his postdoctoral training in the lab of Dr. Kounosuke Watabe at Wake Forest School of Medicine where he researched various aspects of tumor metastasis including discovery of novel radiofrequency electromagnetic field’s efficacy in regressing brain metastasis, identifying metastasis mediator genes by CRISPR library screening, and delineating the biology of neutrophils and macrophage in metastasis. Sambad earned his Ph.D in Cancer Biology from Wake Forest school of medicine where he studied the role of microenvironment in prostate cancer dormancy in bone. He established a novel in vivo model which recapitulated dormancy and recurrence of cancer in bone and identified critical molecules/pathways associated with dormancy. He was also involved in studies that discovered the role of miRNAs and lncRNAs in breast tumor progression.